H5N1 News and Research RSS Feed - H5N1 News and Research Twitter

Influenza A (H5N1) virus – also called “H5N1 virus” – is an influenza A virus subtype that occurs mainly in birds, is highly contagious among birds, and can be deadly to them. H5N1 virus does not usually infect people, but infections with these viruses have occurred in humans. Most of these cases have resulted from people having direct or close contact with H5N1-infected poultry or H5N1-contaminated surfaces.
CFDA issues new drug certificate and production license for Sinovac's EV71 vaccine

CFDA issues new drug certificate and production license for Sinovac's EV71 vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that the China Food and Drug Administration issued the new drug certificate and production license for its Enterovirus 71 ("EV71") vaccine. [More]
NIAID scientists successfully test prime-boost H7N9 influenza vaccine concept in clinical trial

NIAID scientists successfully test prime-boost H7N9 influenza vaccine concept in clinical trial

In clinical trials, several candidate H7N9 pandemic influenza vaccines made from inactivated viruses have been shown to be safe and to generate an immune response. However, scientists believe for practical use, these potential vaccines would require multiple doses or the addition of adjuvants, which enhance the immune response. [More]
Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on its Sabin Inactivated Polio Vaccine (or "sIPV") candidate. [More]
Study reveals molecular function of protein essential for replication of H5N1 flu virus

Study reveals molecular function of protein essential for replication of H5N1 flu virus

An international collaboration of scientists from the CEA, CNRS, University Joseph Fourier, the EMBL and the ILL has revealed the molecular function of a protein essential for replication of H5N1 influenza virus. [More]
Researchers use genomic techniques to show why different strains of Salmonella infect particular animal species

Researchers use genomic techniques to show why different strains of Salmonella infect particular animal species

It's called bird flu for a reason. Particular characteristics about the influenza virus known as H5N1 allow it to primarily affect avifauna, though in some worrying cases the disease has been passed to humans. [More]
Australian researchers find a way to boost cross-protective capabilities of influenza A vaccine

Australian researchers find a way to boost cross-protective capabilities of influenza A vaccine

Australian researchers have found a way to boost the effectiveness and cross-protective capabilities of an influenza A vaccine by adding a simple component. Published this week in mBio, an online open-access journal of the American Society for Microbiology, the research in mice could lead to better seasonal flu vaccines for humans, and also vaccines that could provide community protection in the early stages of an outbreak of a novel flu virus strain. [More]
Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received approval to begin human clinical trials on its varicella vaccine candidate. The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration in January 2013. [More]
BiondVax to begin Phase IIb clinical trial of universal influenza vaccine in Europe

BiondVax to begin Phase IIb clinical trial of universal influenza vaccine in Europe

BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium. [More]
Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Long lasting flu vaccine using antibodies advance from TSRI and Janssen

Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots. [More]
TSRI, Janssen collaborate to find universal flu vaccine

TSRI, Janssen collaborate to find universal flu vaccine

Scientists from The Scripps Research Institute and the Janssen Pharmaceutical Companies of Johnson & Johnson have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots. [More]
NanoViricides speeds up HerpeCide drug development program

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program. [More]
Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC. [More]
Researchers devise way to induce protective immunity in mice against influenza viruses

Researchers devise way to induce protective immunity in mice against influenza viruses

A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain. [More]
Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

Researchers create new vaccine development method for H5N1, H7N9 strains of avian influenza

A recent study with Kansas State University researchers details vaccine development for two new strains of avian influenza that can be transmitted from poultry to humans. The strains have led to the culling of millions of commercial chickens and turkeys as well as the death of hundreds of people. [More]
Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

Non-coding RNAs in maternal food can pass through placenta to regulate fetal gene expression

In a new study published in the Protein & Cell, Chen-Yu Zhang's group at Nanjing University reports that small non-coding RNAs in maternal food can transfer through placenta to regulate fetal gene expression. [More]
NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection. [More]
Simple, effective portable tool can help predict avian flu outbreaks

Simple, effective portable tool can help predict avian flu outbreaks

A simple and effective portable tool to predict avian flu outbreaks on farms has been created by University of Guelph researchers. [More]
HPAI H5 viruses of Eurasian origin continue to circulate in North American wild birds

HPAI H5 viruses of Eurasian origin continue to circulate in North American wild birds

Highly pathogenic avian influenza (HPAI) H5 viruses of Eurasian origin continue to circulate and evolve in North American wild birds. [More]
New antibody provides 100% protection against H5N1 influenza virus in animal models

New antibody provides 100% protection against H5N1 influenza virus in animal models

Since 2003, the H5N1 influenza virus, more commonly known as the bird flu, has been responsible for the deaths of millions of chickens and ducks and has infected more than 650 people, leading to a 60 percent mortality rate for the latter. Luckily, this virus has yet to achieve human-to-human transmission, but a small number of mutations could change that, resulting in a pandemic. [More]
NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs. [More]
Advertisement
Advertisement